Euronet Worldwide Reports Second Quarter 2025 Financial Results – Highlighted by 13% Operating Income Growth GlobeNewswire July 31, 2025 Digital growth strategy accelerated with the announced acquisition of leading credit card issuing platform Ren signs agreement with top tier United States bank Money Transfer expands digital remittance through Google partnership Money Transfer enters Japanese market […]

NEW YORK CITY, NY / ACCESS Newswire / July 30, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Simulations Plus, Inc. ("Simulations Plus, Inc.") (NASDAQ:SLP) concerning possible violations of federal securities laws. Simulations Plus reported its financial results for its third fiscal quarter on July 14, 2025. Among other

Edelson Lechtzin LLPis investigating potential violations of the federal securities laws involvingCharter Communications, Inc. (“Charter”) (NASDAQ: CHTR), resulting from allegations of providing potentially misleading business information to the investing public. https://mma.prnewswire.com/media/2457789/logo2_Logo.jpg If you are a Charter investor who suffered a loss and would like to learn more, you can provide your information HERE. You can

Shoulder Innovations, Inc. (“Shoulder Innovations”), a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, today announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a public offering price of $15.00 pershare. https://mma.prnewswire.com/media/779412/Shoulder_Innovations_Logo.jpg In addition, Shoulder Innovations has granted the underwriters a 30-day option

Edelson Lechtzin LLPis investigating potential violations of the federal securities laws involvingSimulations Plus, Inc. (“Simulations Plus”) (NASDAQ: SLP), resulting from allegations of providing potentially misleading business information to the investing public. https://mma.prnewswire.com/media/2457789/logo2_Logo.jpg If you are a Simulations Plus investor who suffered a loss and would like to learn more, you can provide your information HERE.

TECNO, an AI-driven innovative technology brand, has unveiled the Sandy Titanium Edition of its acclaimed CAMON 40 Series. Drawing inspiration from the desert's metallic glimmer at dusk and the timeless beauty of precious metals, the new edition delivers a subtle, understated finish that embodies quiet strength, resilience, and modern elegance. TECNO launches the new CAMON

Activeo, a trusted system integrator in customer experience transformation, today announced the launch of Activeo OneView CSM, a powerful integration that unifies contact centre platforms with ServiceNow Customer Service Management (CSM). Purpose-built to eliminate silos, Activeo OneView CSM empowers enterprises to deliver faster, more personalised, and more efficient customer service from a single interface. https://mma.prnewswire.com/media/2740916/Activeo_OneView_CSM__2.jpg

Reduce Weekly Business Pain Points by Up to 6 Hours – Digital business solutions provider Osomeand Aspire, a leading all-in-one finance platform for modern businesses, have deepened their partnership to help entrepreneurs in Singapore and Hong Kong save time and reduce repetitive financial admin. Through Aspire'sbank integration now available on Osome's AI-enabled all-in-one platform, founderscan

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito,"Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A.Viehbacher, "Biogen") announced today that the two-year real-world study in the U.S of lecanemab (generic name, product name: LEQEBMI(R)), an anti-AB protofibril* antibody, was presented at the Alzheimer's Association International Conference (AAIC) 2025, held in Toronto,

Akeso, Inc. (9926.HK) (“Akeso” or the “Company”) announced that the first patient has been dosed in its pivotal Phase III clinical study (AK112-305/HARMONi-8A) of ivonescimab (PD-1/VEGF bispecific antibody) in combination with docetaxel for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) that has progressed following PD-1/L1 inhibitors and platinum-based chemotherapy. Ivonescimab